



## Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-023-02758-x>,  
published online 8 January 2024.

<https://doi.org/10.1038/s41591-024-02898-8>

Published online: 06 March 2024



Yara L. Verschoor , Joris van de Haar , José G. van den Berg, Johanna W. van Sandick, Liudmila L. Kodach, Jolanda M. van Dieren , Sara Balduzzi , Cecile Grootsholten, Marieke E. IJsselsteijn, Alexander A. F. A. Veenhof, Koen J. Hartemink, Marieke A. Vollebergh, Adham Jurdi , Shruti Sharma, Erik Spickard , Emilia C. Owers, Annemarieke Bartels-Rutten, Peggy den Hartog, Noel F. C. C. de Miranda , Monique E. van Leerdam , John B. A. G. Haanen , Ton N. Schumacher , Emile E. Voest & Myriam Chalabi

In the version of the article initially published, the Data Availability section and Reporting Summary contained the wrong accession code for the data deposited in the European Genome-Phenome Archive. This has now been updated to “[EGASS0000000168](#)” in the HTML and PDF versions of the article.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024